Endologix Holdings has announced Rhevera Medical as its new corporate brand—an updated identity that reflects the company’s broader commitment to partnering with physicians who treat complex vascular disease, and supporting patients whose lives, mobility and independence depend on the company’s technologies, as stated in a press release.
For decades, Endologix has worked alongside physicians who care for patients with serious vascular conditions, including abdominal aortic aneurysms (AAAs) and peripheral arterial disease (PAD). As the company has expanded beyond aortic repair into percutaneous bypass and mechanical thrombectomy, its purpose has remained centred on the “simple clinical need” to “preserve blood flow where it is threatened and restore it where it has been lost”.
Rhevera Medical “brings that purpose forward” through a portfolio designed for physicians managing some of the most challenging vascular cases, the recent release adds. The company’s technologies include the Alto abdominal stent graft system, the AFX2 endovascular AAA system, the Detour system for percutaneous bypass in PAD, and the Pounce thrombectomy system. Together, these platforms are intended to give physicians meaningful options when conventional approaches may not fully address a patient’s clinical needs.
“Our name has changed because the needs of physicians and patients have expanded,” said John Liddicoat, president and chief executive officer (CEO) of Rhevera Medical. “Rhevera Medical reflects who we are becoming: a company focused on helping physicians preserve and restore blood flow for patients facing serious vascular disease. Whether a patient is at risk from an aneurysm, threatened by limb ischaemia, or experiencing an acute vessel blockage, our work begins with the clinical reality physicians face and the outcomes patients are counting on.”
Rhevera combines ‘rheo’, which is Greek for ‘flow’, and ‘vera’, which is Latin for ‘true’. The name expresses the company’s focus on true, sustained blood flow across its therapies, and the clinical outcomes physicians and patients seek, according to Rhevera Medical’s press release.
“Rhevera Medical represents a clear commitment to the physicians who take on difficult vascular cases and to the patients who need dependable treatment options,” commented John Martin, senior clinical advisor, Vascular Therapies, at Rhevera Medical. “Our goal is to support clinical decision-making with technologies that are differentiated, evidence led and built around the realities of patient care.”
